LNSR
HEALTHCARELENSAR Inc
$5.38-0.10 (-1.73%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LNSR Today?
No stock-specific AI insight has been generated for LNSR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.06$14.31
$5.39
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-2.87
Dividend Yield—
Dividend / Share—
ROE-10.7%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume52K
Avg Volume (10D)—
Shares Outstanding12.1M
LNSR News
21 articles- [Form 4] LENSAR, Inc. Insider Trading ActivityStock Titan·May 9, 2026
- LENSAR Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- LENSAR® Reports First Quarter 2026 Results and Provides Business UpdateYahoo Finance·May 8, 2026
- LENSAR® to Report First Quarter 2026 Results on May 8, 2026Yahoo Finance·Apr 30, 2026
- How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside PotentialYahoo Finance·Apr 21, 2026
- Cedar Grove Capital Management’s Views on LENSAR (LNSR)Yahoo Finance·Apr 20, 2026
- How The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target ResetYahoo Finance·Apr 5, 2026
- LENSAR Inc (LNSR) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst ChallengesYahoo Finance·Apr 4, 2026
- LENSAR, Inc. Q4 2025 Earnings Call SummaryMoby·Apr 1, 2026
- LENSAR Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business UpdateYahoo Finance·Mar 31, 2026
- BYND And LNSR Set The Tone TuesdayYahoo Finance·Mar 17, 2026
- Fed Kicks Off Policy Meeting as US Equity Futures Tread Water Pre-BellYahoo Finance·Mar 17, 2026
- Alcon abandons effort to purchase LENSAR after FTC scrutinyMedtechdive·Mar 17, 2026
- Alcon and LENSAR, Inc. Agree to Terminate Merger AgreementYahoo Finance·Mar 16, 2026
- LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLCYahoo Finance·Mar 16, 2026
- LENSAR® Provides Update on Pending Acquisition by AlconYahoo Finance·Feb 25, 2026
- LENSAR® Reports Third Quarter 2025 Results and Provides Business UpdateYahoo Finance·Nov 6, 2025
- LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Sep 2, 2025
- SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of DirectorsYahoo Finance·Aug 19, 2025
- LENSAR Reports Second Quarter 2025 Results and Provides Business UpdateYahoo Finance·Aug 7, 2025
All 21 articles loaded
Price Data
Open$5.48
Previous Close$5.48
Day High$5.55
Day Low$5.26
52 Week High$14.31
52 Week Low$5.06
52-Week Range
$5.06$14.31
$5.39
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-2.87
Dividend Yield—
Dividend / Share—
ROE-10.7%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume52K
Avg Volume (10D)—
Shares Outstanding12.1M
About LENSAR Inc
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—